News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
INNOCARE (09969.HK): Orelabrutinib Approved in Australia for Treatment of Adult Lymphoma Patients
INNOCARE (09969.HK) announced that orelabrutinib (Hibruka) has been approved by the Therapeutic Goods Administration (TGA) in Australia for the treatment of adult patients with rel...
Reset
Send
The window will close in 5 seconds
INNOCARE (09969.HK): Orelabrutinib Approved in Australia for Treatment of Adult Lymphoma Patients
Close
Recommend
2
Positive
4
Negative
0
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get 1 Intel/Selected Gold ETF share!

INNOCARE (09969.HK)  -0.180 (-1.639%)    Short selling $13.99M; Ratio 14.428%   announced that orelabrutinib (Hibruka) has been approved by the Therapeutic Goods Administration (TGA) in Australia for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (r/r MCL). (jl/a)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-06-03 16:25.)

Related News M Stanley Ratings and TPs on China Biotech Stocks

Auto-translated by AI
View Original Text
This article was automatically translated by AI, the original language version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation.

AASTOCKS Financial News
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.